These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The renin-angiotensin system and vascular fibrinolytic balance. Agirbasli M; Vaughan DE Int J Clin Pract Suppl; 1998 May; 94():20-5. PubMed ID: 9926441 [TBL] [Abstract][Full Text] [Related]
8. The plasminogen activator system and cancer. McMahon B; Kwaan HC Pathophysiol Haemost Thromb; 2008; 36(3-4):184-94. PubMed ID: 19176991 [TBL] [Abstract][Full Text] [Related]
9. [PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms]. Banfi C; Mussoni L; Tremoli E Minerva Endocrinol; 2002 Sep; 27(3):181-91. PubMed ID: 12091793 [TBL] [Abstract][Full Text] [Related]
10. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. Panahloo A; Yudkin JS J Cardiovasc Risk; 1997 Apr; 4(2):91-9. PubMed ID: 9304490 [No Abstract] [Full Text] [Related]
11. [Role of plasminogen activator inhibitor type 1 in tumor angiogenesis]. Bajou K; Devy L; Masson V; Albert V; Frankenne F; Noël A; Foidart JM Therapie; 2001; 56(5):465-72. PubMed ID: 11806282 [TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). Chorostowska-Wynimko J; Skrzypczak-Jankun E; Jankun J Int J Mol Med; 2004 Jun; 13(6):759-66. PubMed ID: 15138609 [TBL] [Abstract][Full Text] [Related]
14. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Yamamoto K; Takeshita K; Kojima T; Takamatsu J; Saito H Cardiovasc Res; 2005 May; 66(2):276-85. PubMed ID: 15820196 [TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Nordt TK; Peter K; Ruef J; Kübler W; Bode C Thromb Haemost; 1999 Sep; 82 Suppl 1():14-8. PubMed ID: 10695479 [TBL] [Abstract][Full Text] [Related]
16. Fibrinolytic factors and atherothrombotic events: epidemiological evidence. Folsom AR Ann Med; 2000 Dec; 32 Suppl 1():85-91. PubMed ID: 11209988 [TBL] [Abstract][Full Text] [Related]
17. Vascular functions of the plasminogen activation system. Fay WP; Garg N; Sunkar M Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1231-7. PubMed ID: 17379840 [TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis and the risk of venous and arterial thrombosis. Meltzer ME; Doggen CJ; de Groot PG; Rosendaal FR; Lisman T Curr Opin Hematol; 2007 May; 14(3):242-8. PubMed ID: 17414214 [TBL] [Abstract][Full Text] [Related]
19. The 'PAI-1 paradox' in vascular remodeling. Diebold I; Kraicun D; Bonello S; Görlach A Thromb Haemost; 2008 Dec; 100(6):984-91. PubMed ID: 19132221 [TBL] [Abstract][Full Text] [Related]
20. Diabetes mellitus as a prothrombotic condition. Grant PJ J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]